Skip to main content

Market Overview

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

The CNBC Healthy Returns Conference recently came to an end, and Leerink analyst Ana Gupte summarized the key takeaways from the event in a note on Thursday. Here’s what investors need to know:

  • According to venture capital and private equity investors, one of the largest investment opportunities in the health care space is gene therapy for the treatment of cancer, Alzheimer’s and Parkinson’s Disease. Gupte also said the health care services industry is exploding in size and scope.
  • A panel of experts said, Inc. (NASDAQ: AMZN) will likely take one of three paths in health care: become an aggregator of current products and services, completely disrupt the current supply chain structure or provide the underlying technology for the next generation of health care.
  • CIGNA Corporation (NYSE: CI) CEO David Cordani discussed his vision for the future of the company. “An open architecture, collaborative network approach is preferred rather than one specific, owned care delivery model,” Gupte said.
  • Technology can provide new means of diagnosis and treatment. For example, virtual reality therapy is being tested for acute and chronic pain management.
  • Modern medicine and technology is on the brink of dramatically expanding the human life expectancy, driven my new early detection methods for deadly conditions.

Leerink analyst Bradley Canino also initiated coverage of Radius Health Inc (NASDAQ: RDUS) on Thursday with an Outperform rating and $53 price target.

“Tymlos is off to a promising start, and the company is advancing a unique and proprietary transdermal patch version of the medicine,” Canino wrote.

Related Links:

Biotech Winners And Losers From Congress' Latest Funding Bill

Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'

Latest Ratings for AMZN

Apr 2021Credit SuisseMaintainsOutperform
Apr 2021Evercore ISI GroupAssumesOutperform
Feb 2021CitigroupMaintainsBuy

View More Analyst Ratings for AMZN
View the Latest Analyst Ratings


Related Articles (AMZN + CI)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Health Care Price Target Initiation Events Analyst Ratings Best of Benzinga

Latest Ratings

SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at